👀 Ones to watch: The MOST undervalued shares to buy right nowSee Undervalued Shares

GOP Congress Members To DEA Chief Milgram: Why Haven't You Signed Cannabis Rescheduling Proposal?

Published 23/05/2024, 22:11
© Reuters.  GOP Congress Members To DEA Chief Milgram: Why Haven\'t You Signed Cannabis Rescheduling Proposal?

Benzinga - by Maureen Meehan, Benzinga Editor.

Congressional members Rep. Andrew Clyde (R-GA) and Rep. Ben Cline (R-VA) are demanding answers from DEA administrator Anne Milgram about why she did not sign the recent White House proposal to reschedule cannabis rather than having it approved by Attorney General Merrick Garland, thus breaking with "decades of precedent."

What Happened: Shortly after President Joe Biden announced plans on April 30 to reclassify cannabis as a Schedule III substance, the Department of Justice (DOJ) followed with an announcement that AG Garland had formally initiated the rescheduling process with the submission of a legal review. This break in precedent is fueling speculation that the DEA or Milgram disagree with the rescheduling decision.

Where Is The DEA?

In their letter sent to Milgram, reported Marijuana Moment (MM), Reps. Clyde and Cline also expressed "grave concern" about her "refusal to respond to questions from multiple members" regarding cannabis scheduling earlier this month at a House Appropriations subcommittee hearing. At that meeting, Milgram told lawmakers that it would be “inappropriate” for her to comment on the agency’s recent marijuana rescheduling determination because the rule-making process was “ongoing.”

The Congress members took Milgram to task for that comment, saying "you were legally compelled to testify and answer questions related to marijuana reclassification despite your refusal and your incorrect legal interpretation of the APA [Administrative Procedure Act]."

Then They Got Demanding

"Accordingly, we expect to receive answers to the questions asked by members during the hearing," they said, adding that they also expect Milgram to respond to any written Questions for the Record (QFRs) from subcommittee members related to the issue, noted MM's Kyle Jaeger.

In their letter, Reps Clyde and Cline asked Milgram to explain why she has not signed the rescheduling notice and whether the Department of Justice provided justification for this unusual step. They requested answers by June 5, to review before the subcommittee's budget markup session.

Photo: Benzinga edit with images by US Government, U.S. Drug Enforcement Agency via Wikimedia Commons and Cambridge Jenkins IV on Unsplash

Related story: DEA Vs. Dept Of Justice Over Cannabis Rescheduling: Too Many Cooks In The Kitchen?

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.